VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
LLYEli Lilly and Company
$1098.13$1.04T
Research
OverviewAnalysisShould I Buy?
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksLLYP/E History

LLY logoEli Lilly and Company (LLY) P/E Ratio History

Undervalued

Trading at 47.8x vs 5Y avg 63.8x · 35th percentile · Below historical baseline · Data 1990–2026

Current P/E (TTM)
47.8x
-25% vs 5Y avg
5Y Avg P/E
63.8x
Median 54.6x
5Y Percentile
35th
Mid-range
PEG Ratio
1.66
Aligned with growth
5-Year P/E Range
47.8x
Min32.7xMedian54.6xMax116.1x
TTM EPS$28.21
Price$1098.13
Earnings Yield2.09%
EPS Growth (1Y)96.0%
EPS Growth (5Y)28.8%

Loading P/E history...

P/E Ratio Analysis

As of June 21, 2026, Eli Lilly and Company (LLY) trades at a price-to-earnings ratio of 47.8x, with a stock price of $1098.13 and trailing twelve-month earnings per share of $28.21.

The current P/E is 25% below its 5-year average of 63.8x. Over the past five years, LLY's P/E has ranged from a low of 32.7x to a high of 116.1x, placing the current valuation at the 35th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, LLY trades at a 116% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

The PEG ratio of 1.66 (P/E divided by 96% EPS growth) suggests a fair valuation relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.

Relative to the broader market, LLY commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our LLY DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

LLY Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
47.8vs22.1
+116%
Above Sector
vs. S&P 500
47.8vs24.4
+96%
Above Market
PEG Analysis
1.66
P/E ÷ EPS Growth
PEG 1-2 = Fair
Based on 96% EPS growth (1Y)

LLY P/E vs Peers

Large diversified branded pharma peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
NVO logoNVONovo Nordisk A/S
$192B12.2Lowest0.59Best+2%
PFE logoPFEPfizer Inc.
$143B18.5--4%
MRK logoMRKMerck & Co., Inc.
$281B15.60.74+8%
AZN logoAZNAstraZeneca PLC
$271B26.71.23+191%Best
BMY logoBMYBristol-Myers Squibb Company
$110B15.7-+178%
ABBV logoABBVAbbVie Inc.
$383B91.4--1%
JNJ logoJNJJohnson & Johnson
$550B39.4--58%
NVS logoNVSNovartis AG
$281B20.51.33+22%
AMGN logoAMGNAmgen Inc.
$182B23.78.07+88%
BIIB logoBIIBBiogen Inc.
$29B22.3--21%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

LLY Historical P/E Data (1990–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q1-$919.77$28.1532.7x+2%
FY2025 Q4Dec 31 2025$1074.68$22.9546.8x+47%
FY2025 Q3-$763.00$20.4437.3x+17%
FY2025 Q2Jun 30 2025$779.53$15.3050.9x+60%
FY2025 Q1Mar 31 2025$825.91$12.2967.2x+111%
FY2024 Q4-$772.00$11.7165.9x+107%
FY2024 Q3Sep 30 2024$885.94$9.2595.8x+200%
FY2024 Q2Jun 30 2024$905.38$8.12111.5x+250%
FY2024 Q1Mar 31 2024$777.96$6.70116.1x+264%
FY2023 Q4Dec 31 2023$582.92$5.64103.4x+224%
FY2023 Q3Sep 30 2023$537.13$5.26102.1x+220%
FY2023 Q2Jun 30 2023$468.98$6.9367.7x+112%
FY2023 Q1Mar 31 2023$343.42$6.1256.1x+76%
FY2022 Q4Dec 31 2022$365.84$6.7054.6x+71%
FY2022 Q3Sep 30 2022$323.35$6.4750.0x+57%
FY2022 Q2-$324.23$6.0253.9x+69%
FY2022 Q1-$286.37$6.5044.1x+38%
FY2021 Q4Dec 31 2021$276.22$5.9146.7x+47%
FY2021 Q3-$231.05$6.3136.6x+15%
FY2021 Q2Jun 30 2021$229.52$6.4135.8x+12%
FY2021 Q1Mar 31 2021$186.82$6.3629.4x-8%
FY2020 Q4-$168.84$6.4726.1x-18%
FY2020 Q3Sep 30 2020$148.02$5.8225.4x-20%
FY2020 Q2-$164.18$5.8728.0x-12%
FY2020 Q1-$138.72$5.7624.1x-24%
FY2019 Q4-$131.43$8.5515.4x-52%
FY2019 Q3Sep 30 2019$111.83$8.0913.8x-57%
FY2019 Q2Jun 30 2019$110.79$7.9014.0x-56%
FY2019 Q1Mar 31 2019$129.76$6.2820.7x-35%
FY2018 Q4Dec 31 2018$115.72$3.1337.0x+16%
FY2018 Q3Sep 30 2018$107.31$0.53202.5x+535%
FY2018 Q1Mar 31 2018$77.37$1.0772.3x+127%
FY2017 Q3Sep 30 2017$85.54$2.0142.6x+33%
FY2017 Q2Jun 30 2017$82.30$2.2137.2x+17%
FY2017 Q1Mar 31 2017$84.11$1.9842.5x+33%
FY2016 Q4Dec 31 2016$73.55$2.4829.7x-7%
FY2016 Q3Sep 30 2016$80.26$2.2136.3x+14%
FY2016 Q2-$78.75$2.2335.3x+11%
FY2016 Q1-$72.01$2.0934.5x+8%
FY2015 Q4-$84.26$2.1738.8x+22%
FY2015 Q3Sep 30 2015$83.69$2.1339.3x+23%
FY2015 Q2-$83.49$1.8644.9x+41%
FY2015 Q1-$72.65$1.9836.7x+15%
FY2014 Q4Dec 31 2014$68.99$2.1532.1x+1%
FY2014 Q3-$64.85$2.4126.9x-16%
FY2014 Q2Jun 30 2014$62.17$3.0320.5x-36%
FY2014 Q1Mar 31 2014$58.86$3.4417.1x-46%
FY2013 Q4-$51.00$4.1612.3x-62%
FY2013 Q3Sep 30 2013$50.33$4.2311.9x-63%
FY2013 Q2Jun 30 2013$49.12$4.3411.3x-65%
FY2013 Q1Mar 31 2013$56.79$4.1013.9x-57%
FY2012 Q4Dec 31 2012$49.32$3.6413.5x-58%
FY2012 Q3Sep 30 2012$47.41$3.6912.8x-60%
FY2012 Q2Jun 30 2012$42.91$3.6211.9x-63%
FY2012 Q1Mar 31 2012$40.27$3.8610.4x-67%
FY2011 Q4Dec 31 2011$41.56$3.9010.7x-67%
FY2011 Q3Sep 30 2011$36.97$4.188.8x-72%
FY2011 Q2-$37.53$4.258.8x-72%
FY2011 Q1-$35.17$4.408.0x-75%
FY2010 Q4Dec 31 2010$35.04$4.587.7x-76%
FY2010 Q3-$36.53$4.368.4x-74%
FY2010 Q2Jun 30 2010$33.50$4.048.3x-74%
FY2010 Q1Mar 31 2010$36.22$3.889.3x-71%
FY2009 Q4-$35.71$3.959.0x-72%
FY2008 Q3-$44.03$2.2020.0x-37%
FY2008 Q2Jun 30 2008$46.16$3.4813.3x-58%
FY2008 Q1Mar 31 2008$51.59$3.2116.1x-50%
FY2007 Q4Dec 31 2007$53.39$2.7119.7x-38%
FY2007 Q3Sep 30 2007$56.93$2.0527.8x-13%
FY2007 Q2Jun 30 2007$55.88$2.0027.9x-12%
FY2007 Q1Mar 31 2007$53.71$2.1525.0x-22%
FY2006 Q4Dec 31 2006$52.10$2.4521.3x-33%
FY2006 Q3Sep 30 2006$57.00$2.9719.2x-40%
FY2006 Q2Jun 30 2006$55.27$2.9019.1x-40%
FY2006 Q1Mar 31 2006$55.30$1.9129.0x-9%
FY2005 Q4Dec 31 2005$56.59$1.8231.1x-2%
FY2005 Q3Sep 30 2005$53.52$1.1845.4x+43%
FY2005 Q2-$55.71$1.1449.0x+54%
FY2005 Q1-$52.10$1.9726.5x-17%
FY2004 Q4Dec 31 2004$56.75$1.6634.2x+7%
FY2004 Q3-$60.05$2.3525.6x-20%
FY2004 Q2Jun 30 2004$69.91$2.3230.1x-5%
FY2004 Q1Mar 31 2004$66.90$2.3628.3x-11%
FY2003 Q4Dec 31 2003$70.33$2.3729.7x-7%
FY2003 Q3-$59.40$2.3625.2x-21%
FY2003 Q2Jun 30 2003$68.97$2.3329.6x-7%
FY2003 Q1Mar 31 2003$57.15$2.3024.8x-22%
FY2002 Q4-$63.50$2.5025.4x-20%
FY2002 Q3Sep 30 2002$55.34$2.3523.5x-26%
FY2002 Q2Jun 30 2002$56.40$2.2425.2x-21%
FY2002 Q1Mar 31 2002$76.20$2.3931.9x-0%
FY2001 Q4Dec 31 2001$78.54$2.5530.8x-3%
FY2001 Q3Sep 30 2001$80.70$2.7229.7x-7%
FY2001 Q2Jun 30 2001$74.00$2.9125.4x-20%
FY2001 Q1Mar 31 2001$76.66$2.7627.8x-13%
FY2000 Q4Dec 31 2000$93.06$2.7933.4x+5%
FY2000 Q3Sep 30 2000$81.13$2.8029.0x-9%
FY2000 Q2Jun 30 2000$99.88$2.7636.2x+13%
FY2000 Q1Mar 31 2000$62.63$2.6723.5x-26%
FY1999 Q4Dec 31 1999$66.50$2.4627.0x-15%
FY1999 Q3-$64.19$2.2628.4x-11%
FY1999 Q2Jun 30 1999$71.63$2.0534.9x+10%
FY1999 Q1Mar 31 1999$84.88$1.9743.1x+35%
FY1998 Q4-$88.88$1.8747.5x+49%
FY1998 Q3Sep 30 1998$78.31$1.7644.5x+40%
FY1998 Q2-$66.25$1.7039.0x+22%
FY1997 Q1Mar 31 1997$41.13$1.3929.6x-7%
FY1996 Q4-$36.50$1.3626.8x-16%
FY1996 Q3Sep 30 1996$32.25$1.3324.2x-24%
FY1996 Q2Jun 30 1996$32.50$2.0415.9x-50%
FY1996 Q1Mar 31 1996$32.50$2.0216.1x-50%
FY1995 Q4Dec 31 1995$28.13$2.0213.9x-56%
FY1995 Q3Sep 30 1995$22.47$1.9711.4x-64%
FY1995 Q2Jun 30 1995$19.63$1.1716.8x-47%
FY1995 Q1Mar 31 1995$18.28$1.1815.5x-51%
FY1994 Q4Dec 31 1994$16.41$1.1214.7x-54%
FY1994 Q3Sep 30 1994$14.47$0.4333.7x+6%
FY1994 Q2-$14.22$0.4035.5x+11%
FY1994 Q1-$12.47$0.4031.2x-2%
FY1993 Q4Dec 31 1993$14.84$0.4235.3x+11%
FY1993 Q3-$12.50$1.1311.1x-65%
FY1993 Q2Jun 30 1993$12.31$0.6518.9x-41%
FY1993 Q1Mar 31 1993$12.19$0.6419.0x-40%
FY1992 Q4-$15.19$0.7121.4x-33%
FY1992 Q3Sep 30 1992$15.66$0.7122.1x-31%
FY1992 Q2-$16.28$1.2013.6x-57%
FY1992 Q1-$17.75$1.1815.0x-53%
FY1991 Q4-$20.88$1.1418.3x-43%
FY1991 Q3Sep 30 1991$19.94$1.1018.1x-43%
FY1991 Q2Jun 30 1991$17.97$1.0716.8x-47%
FY1991 Q1Mar 31 1991$19.56$1.0418.8x-41%
FY1990 Q4Dec 31 1990$18.31$0.9918.5x-42%
FY1990 Q3Sep 30 1990$17.88$0.9618.6x-42%
FY1990 Q2Jun 30 1990$20.78$0.9222.6x-29%

Average P/E for displayed period: 31.9x

Export Data
Consensus-Based Analysis Tools

Full Stock Analysis

Deep dive into LLY consensus models and risk factors.

View Analysis

Should I Buy LLY?

Wall Street verdict, signals, and target summaries.

See Verdict

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

36+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

LLY — Frequently Asked Questions

Quick answers to the most common questions about buying LLY stock.

What is LLY's P/E ratio?

Eli Lilly and Company (LLY) trailing twelve-month P/E ratio is 47.8x, based on TTM diluted EPS of $28.21. The 5-year average P/E is 63.8x and the historical range spans 32.7x to 116.1x.

Is LLY stock overvalued or undervalued?

LLY trades at 47.8x P/E, below its 5-year average of 63.8x. At the 35th percentile of its historical range (32.7x–116.1x), the stock is priced at a discount to its own history.

Is LLY stock expensive?

No, LLY is not expensive on a historical basis. The current P/E of 47.8x is below the 5-year average of 63.8x and sits at the 35th percentile of its valuation range.

What is LLY's historical P/E range?

Over the past 5 years, LLY's P/E ratio has ranged from 32.7x to 116.1x, with a median of 54.6x and an average of 63.8x. The current P/E of 47.8x places the stock at the 35th percentile of this range. Full historical data spans 1990–2026.

How does LLY's P/E compare to the S&P 500?

LLY trades at 47.8x P/E versus the S&P 500 median of 24.4x. The 96% premium to the market typically reflects higher expected earnings growth or quality.

How does LLY's valuation compare to Healthcare peers?

Eli Lilly and Company P/E of 47.8x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is LLY's PEG ratio?

LLY PEG ratio is 1.66, based on a P/E of 47.8x and EPS growth of 96.0%. A PEG between 1 and 2 suggests valuation aligns with growth expectations — typically considered fair.

What is LLY's earnings yield?

LLY earnings yield is 2.09%, the inverse of its 47.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

LLY P/E Ratio History (1990–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current32.7x
Period Avg63.8x
Range32.7x - 116.1x
Change-9%
20 quartersJun 30, 2021 - Mar 31, 2026